Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
University of Wisconsin, Madison
Mayo Clinic
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC
Neonc Technologies, Inc.
Replimune Inc.
Aulos Bioscience, Inc.
Abramson Cancer Center at Penn Medicine
Melanoma Institute Australia
Dana-Farber Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
University of Washington
ImmunityBio, Inc.
M.D. Anderson Cancer Center
Ocellaris Pharma, Inc.
University of Southern California
Mayo Clinic
Memorial Sloan Kettering Cancer Center
University of Pittsburgh
H. Lee Moffitt Cancer Center and Research Institute
Sotio Biotech Inc.
Memorial Sloan Kettering Cancer Center
Transgene
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
NeoImmuneTech
Incyte Corporation
TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc.
University of Arizona
University of Washington
Fujifilm Pharmaceuticals U.S.A., Inc.
Memgen, Inc.
Pfizer
Incyte Corporation
Memorial Sloan Kettering Cancer Center
Incyte Corporation
University of Virginia
Incyte Corporation
University of Pittsburgh
Marengo Therapeutics, Inc.
UNICANCER
AdventHealth Translational Research Institute